Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Sales (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Return on Sales for 15 consecutive years, with 0.1% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 91.0% to 0.1% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, up 18.0% year-over-year, with the annual reading at 0.13% for FY2025, 18.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.1% at Gyre Therapeutics, down from 0.19% in the prior quarter.
  • The five-year high for Return on Sales was 4.72% in Q2 2022, with the low at 18.31% in Q1 2022.
  • Average Return on Sales over 5 years is 2.96%, with a median of 0.11% recorded in 2024.
  • The sharpest move saw Return on Sales plummeted -1504bps in 2021, then surged 2230bps in 2022.
  • Over 5 years, Return on Sales stood at 4.16% in 2021, then plummeted by -107bps to 0.28% in 2022, then crashed by -1211bps to 3.72% in 2023, then surged by 78bps to 0.81% in 2024, then soared by 113bps to 0.1% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.1%, 0.19%, and 0.06% for Q4 2025, Q3 2025, and Q2 2025 respectively.